APA (7th ed.) Citation

Kawashima, Y., Inomata, M., Saito, R., Morinaga, D., Nogawa, H., Satou, M., . . . Miyauchi, E. (2024). MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202. Annals of Oncology, 35, S1344. https://doi.org/10.1016/j.annonc.2024.07.573

Chicago Style (17th ed.) Citation

Kawashima, Y., et al. "MO34-3 The Efficacy of Combined EGFR-TKI Plus VEGF Inhibitor/cytotoxic Therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202." Annals of Oncology 35 (2024): S1344. https://doi.org/10.1016/j.annonc.2024.07.573.

MLA (9th ed.) Citation

Kawashima, Y., et al. "MO34-3 The Efficacy of Combined EGFR-TKI Plus VEGF Inhibitor/cytotoxic Therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202." Annals of Oncology, vol. 35, 2024, p. S1344, https://doi.org/10.1016/j.annonc.2024.07.573.